Lipid-associated membrane proteins (LAMPs) from 14 Mycoplasma hominis isolates or strains share similar protein and antigenicity profiles. Of 31 human immunodeficiency virus-infected patients from whose samples M. hominis was cultured, 28 tested strongly positive for serum antibodies to M. hominis LAMPs. The remaining 3 serum samples showed low antibody titer to LAMPs from all of the 14 M. hominis isolates or strains, which was likely the result of the compromised immune systems of the patients. Thus, M. hominis LAMPs as a whole are homogenous in antigenicity within the species, despite having many different serotypes. Serological study involving 564 healthy blood donors and 211 patients attending sexually transmitted disease clinics by LAMPs showed that general populations were widely exposed to M. hominis. Women were infected with M. hominis at a younger age than were men. The prevalence of infection increased markedly among sexually active persons.
Lipid-associated membrane proteins (LAMPs) from 14 Mycoplasma hominis isolates or strains share similar protein and antigenicity profiles. Of 31 human immunodeficiency virus-infected patients from whose samples M. hominis was cultured, 28 tested strongly positive for serum antibodies to M. hominis LAMPs. The remaining 3 serum samples showed low antibody titer to LAMPs from all of the 14 M. hominis isolates or strains, which was likely the result of the compromised immune systems of the patients. Thus, M. hominis LAMPs as a whole are homogenous in antigenicity within the species, despite having many different serotypes. Serological study involving 564 healthy blood donors and 211 patients attending sexually transmitted disease clinics by LAMPs showed that general populations were widely exposed to M. hominis. Women were infected with M. hominis at a younger age than were men. The prevalence of infection increased markedly among sexually active persons.
Mycoplasmas (also classified as Mollicutes) are the simplest self-replicating microorganisms. The prokaryotic microorganisms lack cell wall structure and many important bacterial biosynthetic pathways [1] . Most mycoplasmal infections in humans are chronic. This may depend on delicate strategies for withstanding damage caused by host immune vigilance. Mycoplasmas have developed sophisticated and unique surface protein properties for self-protection, transportation of metabolic precursors, and interaction with the host cells [2] [3] [4] .
Mycoplasma hominis is a common human urogenital Mycoplasma species. Diseases caused by infection due to M. hominis usually occur after the immune system is compromised, after the respiratory system or urogenital tract is manipulated, after recent surgery, or after trauma. M. hominis infection may involve pelvic inflammation, prostatitis, urethritis, postpartum fever, repeated spontaneous abortion, pyelonephritis, stillbirth, low birth weight, neonatal meningitis, neonatal pneumonia, postabortion fever, and pneumonia [5] [6] [7] [8] [9] [10] [11] [12] . However, most men or women who are colonized with M. hominis in urogenital tracts or oral cavities are clinically asymptomatic.
Mycoplasmal lipid-associated membrane proteins (LAMPs) constitute a major group of the cell surface proteins. They are highly antigenic and are likely the major targets of host antibodies in immune response. Despite frequent phase and size variations of individual components, as a whole, LAMPs of Mycoplasma penetrans, Mycoplasma salivarium, Mycoplasma pirum, Mycoplasma pneumoniae, and Mycoplasma genitalium have been used as target antigens in serological studies to detect serum antibodies to the respective species in patients with various clinical illnesses [13] [14] [15] . Our previous studies showed that serum antibodies to M. genitalium LAMPs have little cross-reactivity to LAMPs from M. pneumoniae, a genomically closely related species, indicating that serological assays that use LAMPs are highly species specific [15] . M. hominis was previously reported to have strain-specific surface antigens and can be classified into several different serotypes [16] . Not knowing which particular serotype of M. hominis is infecting each individual patient has complicated the effective detection of M. hominis-specific antibodies in the previous seroepidemiological studies [16] [17] [18] Institutes of Health, Bethesda, MD). Serum samples obtained from 564 unselected healthy blood donors were also provided by Dr. Harvey J. Alter. Serum samples obtained from 211 unselected HIV-negative patients attending sexually transmitted disease (STD) clinics were collected in San Bernardino, California, and Milwaukee, Wisconsin, and were used in our previous study [13] .
MATERIALS AND METHODS

Mycoplasma
LAMPs preparation.
Preparation of LAMPs was performed as described elsewhere [13] . In brief, M. hominis was cultured in SP4 medium to the beginning of the stationary phase and then collected by centrifugation. Pellets were resuspended in 5 mL of Tris-buffered saline (TBS; 50 mM of TrisCl [pH, 8 .0]; 0.15 M of NaCl) containing 1 mM of EDTA (TBSE), solubilized by adding Triton X-114 to a final concentration of 2%, and incubated at 4ЊC for 1 h. To prepare LAMPs, the Triton X-114 lysate was incubated at 37ЊC for 10 min for phase separation. After centrifugation at 10,000 g for 20 min, the upper aqueous phase was removed and replaced with the same volume of 4ЊC TBSE. The solution was then vortexed and incubated at 4ЊC for 10 min, and the procedures for phase fractionation were repeated twice. The final Triton X-114 phase was resuspended in 4ЊC TBSE to the original volume. Protein concentrations were determined using a protein assay kit (BioRad Laboratories).
ELISA and Western blot tests. ELISA and Western blot procedures were performed as described elsewhere [15, 19] . In brief, LAMPs (1.5 mg/mL) were coated on Nunc-Immuno F96 MaxiSorp plates with 100 mL in each well. After overcoating with 0.1% bovine serum albumin (BSA), 100 mL of human serum or plasma (diluted 1:250 in 10% normal goat serum, 2% BSA, and 3% Nonidet P-40 in PBS) was added to each well. Subsequent steps included addition of 100 mL of 1:1000 biotin-labeled antibody of goat anti-human IgG (Kirkegaard and Perry Laboratories [KPL]) and 1:20,000 peroxidase-labeled streptavidin (KPL) prepared in 10% normal goat serum, 2% BSA, 0.1% NP-40, and 1ϫ PBS (Diluent I). The plates were developed by adding 100 mL of 2,b2-azino-di-[3-ethyl-benzthiazoline-sulfanate] peroxidase substrate solution into each well. The plates were washed 6 times with PBS (pH, 7.2) plus 0.05% NP-40 (Solution A) between each step. In this study, the cutoff value (OD 405 , 10.856) for positivity of M. hominis-specific antibodies was calculated from the mean value of OD 405 readings of 185 antibody-negative blood donors with 4 SDs. Positive samples were repeated in triplicate and tested in plates coated with BSA without LAMPs.
In Western blot analysis, LAMPs of designated amount were separated by SDS-PAGE and transferred to BA-85 nitrocellulose membrane (Schleicher & Schuell). The membrane was blocked with 10% fetal bovine serum and 1% BSA in PBS (pH, 7.2). The membrane was incubated with 50 mL of 1:500 human serum at 25ЊC for 15 h. The membrane was then washed 6 times with PBS (pH, 7.2) plus 0.05% NP-40, incubated at 25ЊC with 1:2000 biotin-labeled goat anti-human IgG for 3 h, incubated at 25ЊC with 1:5000 peroxidase-labeled streptavidin in Diluent I for 90 min, and developed at 37ЊC for 20 min with the 4-chloro-1-naphthol peroxidase substrate system (KPL). SDS-PAGE and stained with Coomassie blue. A duplicate protein gel was immunoblotted with serum obtained from a culture-positive patient (patient 31; see table 1 for details of serum samples) for the antigenicity analysis. Mycoplasmal membrane lipoproteins often demonstrate marked phase and size variation [3, 4] . Although some individual variations were noted, LAMPs from 14 different isolates or strains of M. hominis showed a similar overall protein profile ( figure 1A) . The Western blot also revealed that LAMPs from these 14 different isolates or strains of M. hominis shared antigenic determinants closely (figure 1B). In the antigenicity analysis, many minor LAMP proteins (those that were weakly stained by Coomassie blue) showed strong immunoreactivity ( figure 1A and 1B) .
RESULTS
Protein
Furthermore, we compared the immunoreactivity of LAMPs from isolates or strains with known different serotypes by using serum samples obtained from 2 culture-positive patients (patients 2 and 31). In the study, LAMPs from GTU83, ATCC 43523, ATCC 43522, ATCC 43521, ATCC 43520, ATCC 43519, ATCC 43518, ATCC 23114, and ATCC 15488 were separated by SDS-PAGE and immunoblotted by the above serum diluted at 1:500 (figure 2). The result again revealed that LAMPs from different isolates or strains of M. hominis shared antigenic determinants closely. LAMPs from different strains or isolates produced very similar immunoreactivity profiles by a particular serum sample. However, serum samples obtained from different patients could apparently show different reactivity with LAMP antigens from a particular strain of M. hominis. For example, a serum sample obtained from patient 31 reacted strongly to a LAMP protein of ∼66 kDa found essentially in all of the isolates or strains examined (figure 2B). However, a serum sample obtained from patient 2 showed only weak and varying immunoreactivity with this particular LAMP protein ( figure  2A) .
Testing of serum antibodies to M. hominis by ELISA. We tested serum samples obtained from 31 HIV-positive patients known to be infected with M. hominis by positive urine culture for antibodies to the M. hominis LAMPs by ELISA. Serum samples obtained from 28 of the 31 patients tested strongly positive for IgG antibodies to LAMPs prepared from every one of the 14 different M. hominis isolates or strains. A serum sample obtained from one patient (patient 28) tested positive for the antibodies to only 3 (ATCC 23114, ATCC 43518, and ATCC 43522) of the 14 isolates or strains. The reactivity to LAMPs from the 3 strains or isolates by this serum sample, although classified as positive according to our ELISA cutoff (OD 405 value, 10.856), was significantly lower than those produced by the 28 positive serum samples ( figures 3 and 4) . In the study, serum samples obtained from 2 patients (patients 5 and 26) tested negative by LAMPs from every one of the 14 isolates or strains. One of these 2 patients (patient 26) failed to show any detectable antibodies, even to LAMPs from his own isolate (WWA031). In fact, this patient's serum elicited weaker immunoreactivity to LAMPs of his own isolate than to LAMPs of many other clinical isolates (figure 4). Western blot study confirmed the absence of LAMP-specific antibodies in the patient's serum (figure 5B). In comparison, LAMPs of this patient's isolate were readily recognized by serum samples obtained from other patients ( figure 1B and figure 3) .
M. hominis LAMPs-specific antibody IgG, IgM, and IgA subtypes. In addition to IgG antibodies, we tested serum samples obtained from these 31 M. hominis-infected patients for IgA and IgM antibodies to the M. hominis LAMPs by ELISA. In the study, serum samples were diluted at 1:500 and assayed for IgG, IgM, and IgA by ELISA by using LAMPs from clinical isolate GTU83. Serum samples obtained from 21 Prevalence of IgG antibodies to M. hominis in various human populations.
By using LAMPs from clinical isolate GTU83 as antigens, we tested IgG antibodies by ELISA in serum samples obtained from 564 healthy blood donors and 211 patients attending STD clinics. In the healthy blood donors, 38.8% of women and 30.1% of men were found to be serologically positive. In comparison, the rate of finding positive IgG antibodies was significantly higher in serum samples obtained from patients attending STD clinics (68.6% and 67.2% in women and men, respectively; table 2). We further analyzed the positive rates for M. hominis-specific antibodies between male and female healthy blood donors as well as between different age groups (table 3) .
For female healthy blood donors, the positive rate (∼44%) was evenly distributed in the 3 age groups for ages 20-50 years (table 3) . There was a marked decrease in the 51-60-year-old age group (30.6%) and a further dramatic decrease in the 161-year-old age group (9.1%). Among healthy male blood donors, the positive rate at the age of 20-30 years was 26.7%. However, the positive rate increased considerably in the 31-40-year-old and 41-50-year-old age groups (40.4% and 41.3%, respectively). The rate of serological positivity in men also decreased (to 31.8%) in the 51-60-year old age group and decreased further (to 15.4%) in the group of patients aged 161 years (table 3). The major difference in the infection rate between male and female healthy blood donors lay in the 20-30-yearold age group, which showed a substantially higher rate of M. hominis infection in young women than in young men.
DISCUSSION
Mycoplasmal LAMPs are exposed on the cell surface [3, 20] , highly antigenic [20] , and are likely an important immunogenic targets for hosts' responses in mycoplasmal infections [21] . Antibodies to LAMPs antigens of each individual species of Mycoplasma, contrary to antibodies to many mycoplasmal cytoplasmic proteins, are apparently highly species specific and do not cross-react with those of other species [15] . Mycoplasmal LAMPs as a whole have been used as the target antigens in serological assays detecting M. penetrans-, M. salivarium-, M. pirum-, M. pneumoniae-, and M. genitalium-specific antibodies with a high degree of specificity and sensitivity in serum samples obtained from patients with a wide spectrum of clinical illnesses by our laboratory and others [13, 14] . M. hominis have long been associated with various human diseases. The present study is to examine if LAMPs from M. hominis could also be used in serological assays detecting M. hominis-specific antibodies in patients infected with this Mycoplasma species. However, M. hominis was previously reported to have strain-specific surface antigens and classified into several different serotypes [16] . It is important to examine whether M. hominis LAMPs from one particular strain or isolate can effectively detect antibodies in patients who might be infected with M. hominis of different serotypes.
The protein profiles and antigenicity of LAMPs from 14 different M. hominis strains or clinical isolates were compared by SDS-PAGE and Western blot. Despite known frequent phase and size variations of mycoplasmal LAMPs, LAMPs from all the 14 strains or isolates of M. hominis examined showed rather similar protein profiles ( figure 1A) . Western blot analysis revealed that many M. hominis LAMPs proteins, although expressed at low levels (as revealed by protein staining), were highly immunogenic and showed strong signals when immunoblotted with serum obtained from infected patients (figure 1B). LAMPs from different isolates or strains shared very similar antigenic determinants, as revealed by serum samples from particular patients. On the other hand, the LAMPs from a particular strain or isolate could apparently produce different immunoreaction profiles when blotted with serum samples obtained from different patients ( figure 2A and 2B ). This observation indicates that immune response to particular LAMPs' antigenic determinant may vary in individual hosts.
We tested serum samples obtained from 31 HIV-positive patients known to be infected with M. hominis by urine culture for specific antibodies against LAMPs from each of the 14 different isolates or strains of M. hominis by ELISA. We found that 28 of the 31 patients tested positive for IgG to LAMPs from every one of the 14 different M. hominis strains or isolates. One patient tested weakly positive for the antibodies to 3 of the 14 LAMPs. Two patients tested negative to every one of the 14 LAMPs. The negative or weak positive reactivity to M. hominis LAMPs by these 3 serum samples is most likely the NOTE. Serum samples at a dilution of 1:500 were assayed by ELISA using mycoplasmal lipid-associated membrane proteins from clinical isolate GTU83.
result of the compromised immune state caused by HIV infection of the patients. Indeed, our results showed that one patient (patient 26) failed to mount detectable antibodies to LAMPs from his own isolate (WWA031; figure 4), although LAMPs of this isolate were readily recognized by serum samples obtained from other patients. Our study clearly suggested that LAMPs from any isolate or strain of M. hominis as a whole could be used equally and effectively as ELISA target antigen to detect M. hominis-specific antibodies in serum samples obtained from infected patients, despite the possible existence of many different serotypes. To confirm this finding, 15 serum samples obtained from HIV-negative healthy blood donors who tested positive for antibodies to M. hominis (GTU-83 strain) were further tested against LAMPs from the other 13 different M. hominis strains or isolates. All 15 samples reacted positively to the 13 different M. hominis strains or isolates in ELISA (data not shown).
Although IgM and IgA antibodies could also be detected in some patients, IgG was the most frequently found antibody to M. hominis LAMPs in serum samples obtained from infected patients. No serum sample tested positive for IgM or IgA but negative for IgG to M. hominis LAMPs by ELISA. Our results somewhat differed from the serological findings reported by Brown et al. [18] , who used whole Mycoplasma lysates as target antigens. In their study, the positive rates for IgG, IgM, and IgA of 207 women with M. hominis cultured from lower genital tract specimens were 71%, 82%, and 86%, respectively, whereas the respective rates in our study were 100%, 14%, and 82% (disregarding the 3 serum samples that showed negative results for all 3 immunoglobulin subtypes because of compromised immunity of the corresponding HIV-infected patients). The discrepancy between these 2 studies for the IgG and IgM subtypes could be because whole-cell lysates were used as the antigen target in the other study as well as different patient populations were examined. The low IgM rate in our data and a much higher IgM rate reported in the earlier study (in fact, a higher rate for IgM than IgG) would suggest that most of the patients we studied were chronically infected with M. hominis, and most of their 207 patients were having an acute mycoplasmal infection. However, antigen targets that use whole-cell lysates, including all the household proteins, might have more cross-reactivity with antibodies, particularly IgM, to other mycoplasmal or bacterial agents.
We used M. hominis LAMPs as a whole as an ELISA target antigen to examine the frequencies of M. hominis-specific antibodies in serum samples of different human populations. General populations appear to be widely exposed to M. hominis. Consistent with the earlier finding that M. hominis could be transmitted through sexual contacts [22] , the prevalence of M. hominis-specific antibodies was significantly higher among patients attending STD clinics than among healthy blood donors (67.8% vs. 34.4%). The study also showed that infection of M. hominis occurred in much younger age in women than in men. It is also interesting to find that seropositivity for the Mycoplasma species decreased markedly in the older population in both men and women. The development of ELISA that uses M. hominis LAMPs for rapidly detecting specific antibodies in patients infected with M. hominis would greatly facilitate epidemiological studies of the mycoplasmal infections in various human diseases.
